LataMed AI Corp. (OTC: LMEDD) announced that its 5-for-1 forward stock split became effective at the opening of trading on July 15, 2026, following publication on the FINRA Daily List. The stock split, combined with a mandatory share exchange and a new CUSIP number (21116R404), represents a significant corporate milestone for the development-stage digital health company. Shares will trade under the temporary symbol LMEDD for about 20 business days before reverting to LMED.
According to the company's press release, the forward stock split is designed to adjust the share price and reduce the number of outstanding shares, potentially making the stock more attractive to investors. Shareholders holding shares through brokerage accounts or in electronic book-entry form do not need to take any action, as the corporate action will be processed automatically. Those with physical stock certificates are not required to immediately surrender them, but when presented for transfer or sale, they will be exchanged for the appropriate number of post-split shares under the new CUSIP.
Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., emphasized the importance of the split, stating: "Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms."
The forward stock split is part of broader efforts to strengthen LataMed AI's capital structure as it pursues commercialization of its AI-enabled healthcare solutions. The company focuses on building telehealth infrastructure, healthcare coordination tools, and analytics capabilities for emerging markets, with an initial regional focus on Latin America. Its platforms include CardioAI, PulmoAI, and NeuroAI, which are designed to support healthcare access, patient engagement, provider coordination, emergency medical response, pharmacy integration, insurance accessibility, payment solutions, and data-driven operations.
Investors and shareholders with questions about the exchange process are encouraged to contact their brokerage firm or the company's transfer agent. Additional information is available on LataMed AI's website at https://latamed.ai and through the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
The forward stock split and mandatory share exchange are expected to be completed smoothly, with the temporary trading symbol 'D' designation remaining for approximately 20 business days. The company undertakes no obligation to update forward-looking statements except as required by applicable law.
